Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Recent & Breaking News (OTCQB:RGRX)

RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

PR Newswire October 24, 2022

RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

PR Newswire September 27, 2022

RegeneRx Issues 2022 Letter To Stockholders

PR Newswire August 22, 2022

RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

PR Newswire July 18, 2022

RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

PR Newswire June 22, 2022

Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea

PR Newswire May 4, 2022

RegeneRx Provides Regulatory Update Regarding RGN-259

PR Newswire March 2, 2022

RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health

PR Newswire February 11, 2022

Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury

PR Newswire January 25, 2022

RegeneRx Publishes Regulatory Update on RGN-259

PR Newswire January 12, 2022

RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022

PR Newswire December 17, 2021

RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome

PR Newswire November 29, 2021

Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting

PR Newswire October 29, 2021

Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis

PR Newswire October 6, 2021

New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease

PR Newswire October 5, 2021

RegeneRx Licensee Acquired by Korean Biopharmaceutical Group

PR Newswire September 27, 2021

RegeneRx Issues Letter To Stockholders

PR Newswire July 22, 2021

RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome

PR Newswire July 14, 2021

RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement

PR Newswire July 1, 2021

RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement

PR Newswire June 28, 2021